FDA Brief

Warning letters Drugs

FDA warning letter to

Global Cosmetics Company Limited

High riskIssued Apr 30, 2024Posted May 7, 2024Center for Drug Evaluation and Research | CDER

FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

What happened

FDA reviewed records the company submitted after a September 12, 2022 request for records. It found the company did not adequately test incoming ingredients, including testing ethanol for methanol; lacked adequate stability data; and its quality-control unit did not effectively oversee manufacturing. FDA placed the firm on Import Alert 66-40 on February 16, 2024.

What FDA found

  1. The company did not show that it tests each incoming ingredient for identity, including testing ethanol for methanol.

    21 CFR 211.84(d)(1)
  2. The company lacked adequate stability testing to support storage conditions and expiration dates for its hand sanitizer.

    21 CFR 211.166(a)
  3. The company's quality-control unit did not effectively approve or reject materials and products or oversee quality.

    21 CFR 211.22(a)

What FDA wants

FDA asks the company to respond in writing within 15 working days, stating what it has done to correct the violations and prevent recurrence, or explaining any delay and giving a completion schedule. FDA also recommends a qualified consultant to help meet current good manufacturing practice (CGMP) rules before resuming U.S. drug manufacturing.

Who should pay attention

  • brands that buy OTC drugs or hand sanitizer from this contract manufacturer
  • U.S. importers and distributors of hand sanitizer
  • quality teams qualifying China-made OTC drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk